CN113995846A - 聚乙二醇偶联药物增效剂、其制备方法及用途 - Google Patents
聚乙二醇偶联药物增效剂、其制备方法及用途 Download PDFInfo
- Publication number
- CN113995846A CN113995846A CN202110824029.1A CN202110824029A CN113995846A CN 113995846 A CN113995846 A CN 113995846A CN 202110824029 A CN202110824029 A CN 202110824029A CN 113995846 A CN113995846 A CN 113995846A
- Authority
- CN
- China
- Prior art keywords
- cancer
- reaction
- independently
- group
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 66
- 229940079593 drug Drugs 0.000 title claims abstract description 65
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 239000000543 intermediate Substances 0.000 claims description 32
- 125000003277 amino group Chemical group 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 239000002246 antineoplastic agent Substances 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 229940041181 antineoplastic drug Drugs 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 206010009944 Colon cancer Diseases 0.000 claims description 18
- 206010033128 Ovarian cancer Diseases 0.000 claims description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 11
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 10
- 208000003200 Adenoma Diseases 0.000 claims description 9
- 206010001233 Adenoma benign Diseases 0.000 claims description 9
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 9
- 206010061424 Anal cancer Diseases 0.000 claims description 9
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 206010005949 Bone cancer Diseases 0.000 claims description 9
- 208000018084 Bone neoplasm Diseases 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 206010014733 Endometrial cancer Diseases 0.000 claims description 9
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 9
- 208000032612 Glial tumor Diseases 0.000 claims description 9
- 206010018338 Glioma Diseases 0.000 claims description 9
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 208000000172 Medulloblastoma Diseases 0.000 claims description 9
- 206010027476 Metastases Diseases 0.000 claims description 9
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 9
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 9
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 9
- 206010029260 Neuroblastoma Diseases 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 9
- 206010034299 Penile cancer Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 206010047741 Vulval cancer Diseases 0.000 claims description 9
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 9
- 201000011165 anus cancer Diseases 0.000 claims description 9
- 201000002155 anus sarcoma Diseases 0.000 claims description 9
- 208000002458 carcinoid tumor Diseases 0.000 claims description 9
- 201000010881 cervical cancer Diseases 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 208000024519 eye neoplasm Diseases 0.000 claims description 9
- 201000010175 gallbladder cancer Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000010536 head and neck cancer Diseases 0.000 claims description 9
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 9
- 201000010982 kidney cancer Diseases 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 201000008106 ocular cancer Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 9
- 230000000849 parathyroid Effects 0.000 claims description 9
- 201000000849 skin cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 201000002510 thyroid cancer Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 206010046885 vaginal cancer Diseases 0.000 claims description 9
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 9
- 201000005102 vulva cancer Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000007112 amidation reaction Methods 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 125000003827 glycol group Chemical group 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 238000007259 addition reaction Methods 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 231
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 183
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 167
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- 239000000243 solution Substances 0.000 description 95
- 239000000047 product Substances 0.000 description 90
- 239000012074 organic phase Substances 0.000 description 65
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- 238000003756 stirring Methods 0.000 description 42
- 238000004440 column chromatography Methods 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 35
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 33
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 33
- 238000011068 loading method Methods 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 29
- 238000001704 evaporation Methods 0.000 description 29
- 238000000034 method Methods 0.000 description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 238000010828 elution Methods 0.000 description 22
- 239000000843 powder Substances 0.000 description 21
- 238000000967 suction filtration Methods 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 239000012065 filter cake Substances 0.000 description 20
- 229960005540 iRGD Drugs 0.000 description 20
- 238000005406 washing Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 238000005984 hydrogenation reaction Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 238000005303 weighing Methods 0.000 description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
- 239000003208 petroleum Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012295 chemical reaction liquid Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000000527 sonication Methods 0.000 description 9
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000005909 Kieselgur Substances 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 239000004386 Erythritol Substances 0.000 description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 6
- 229940009714 erythritol Drugs 0.000 description 6
- 235000019414 erythritol Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000011729 BALB/c nude mouse Methods 0.000 description 4
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- CWODDUGJZSCNGB-HQNRRURTSA-N palytoxin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CCCCC[C@H](C)C[C@@H]2[C@@]3(C)C[C@H](C)C[C@@](O3)(CCCCCCC[C@H](O)C[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@](O)(C[C@H](O)[C@@H](C)\C=C\[C@@H](O)CC[C@@H](O)[C@@H](O)[C@H]4O[C@H](C[C@@H](O)[C@H](O)C[C@@H]5[C@H]([C@H](O)[C@@H](O)[C@H](C[C@H](O)\C=C/C=C/C[C@@H](O)[C@H](O)[C@H](O)C\C=C/C(=C)CC[C@H](O)[C@@H](O)[C@H](O)[C@H](C)C[C@@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](\C=C/[C@@H](O)[C@H](O)C[C@H]7O[C@H]8C[C@H](O[C@@H]8CC[C@@H]8[C@@H](C[C@@H](CN)O8)O)C7)O6)O)O5)O)[C@@H](O)[C@H](O)C4)O3)O)O2)[C@H](C[C@H](O)[C@H](O)C(\C)=C\[C@H](O)C[C@@H](C)[C@H](O)C(=O)N\C=C\C(=O)NCCCO)[C@H](O)[C@@H](O)[C@@H]1O CWODDUGJZSCNGB-HQNRRURTSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 3
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- IAOPBESDXLDSMA-UHFFFAOYSA-N azanide;cyclohexylazanide;platinum(2+) Chemical compound [NH2-].[Pt+2].[NH-]C1CCCCC1 IAOPBESDXLDSMA-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229950011068 niraparib Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- CEOCDNVZRAIOQZ-UHFFFAOYSA-N pentachlorobenzene Chemical compound ClC1=CC(Cl)=C(Cl)C(Cl)=C1Cl CEOCDNVZRAIOQZ-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- QEPWHIXHJNNGLU-KRWDZBQOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 QEPWHIXHJNNGLU-KRWDZBQOSA-N 0.000 description 1
- AQTUACKQXJNHFQ-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(O)=O AQTUACKQXJNHFQ-LURJTMIESA-N 0.000 description 1
- NJQOCRDPGFWEKA-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione;hydrochloride Chemical compound Cl.NCCN1C(=O)C=CC1=O NJQOCRDPGFWEKA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- KUYYOUXQOPCFDK-UHFFFAOYSA-N 2-[1-(2-aminoethoxy)ethoxy]ethanamine Chemical compound NCCOC(C)OCCN KUYYOUXQOPCFDK-UHFFFAOYSA-N 0.000 description 1
- YWCIQVCLMJYZBD-UHFFFAOYSA-N 2-tert-butylbutanedioic acid Chemical compound CC(C)(C)C(C(O)=O)CC(O)=O YWCIQVCLMJYZBD-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000010156 Dunnett's T3 test Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FBVSXKMMQOZUNU-NSHDSACASA-N N2,N6-Bis{[(2-methyl-2-propanyl)oxy]carbonyl}lysine Chemical compound CC(C)(C)OC(=O)NCCCC[C@@H](C(O)=O)NC(=O)OC(C)(C)C FBVSXKMMQOZUNU-NSHDSACASA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- DHQUQYYPAWHGAR-KRWDZBQOSA-N dibenzyl (2s)-2-aminopentanedioate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)CC(=O)OCC1=CC=CC=C1 DHQUQYYPAWHGAR-KRWDZBQOSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- -1 hexafluorophosphate Chemical compound 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
技术领域
本发明属医药技术领域,具体涉及聚乙二醇偶联药物增效剂、其制备方法及用途。
背景技术
高分子偶联药物可以大幅度增加药物分子的水溶性;大多数的小分子药物在血液循环中只能保持数分钟,而高分子偶联药物可以保持几十、几百小时甚至更长,这有利于因肿瘤毛细血管的渗漏而产生的“增强渗透和保留”效应(即EPR效应);由于流体力学体积增加而减弱了药物的肾消除,保护药物不被酶降解,延长药物在血浆内的半衰期,增加药物的生物利用度。此外,通过主动靶向或EPR被动靶向使抗癌药高度富集在癌变的器官、组织或细胞,大幅度地降低因为小分子抗癌药充满全身而导致的毒副作用;将药物的细胞吸收局限于内吞路径,有利于向溶酶体方向的药物传输,从而避开p-糖蛋白泵出而导致的抗药性;刺激或恢复免疫功能,利于杀灭癌细胞。
聚乙二醇是高分子偶联药物纳米医学领域最成功的载体,被称之为“黄金标准”载体。过去30年来,聚乙二醇化药物技术取得了巨大的成就,已经有17个聚乙二醇化药物被美国FDA批准进入市场销售,有1个聚乙二醇化药物被中国NMPA批准上市,此外还有近40个临床新药在进行一期、二期、三期临床试验和进入NDA阶段,其中半数为聚乙二醇化小分子药物。
发明内容
本申请是基于发明人对以下事实和问题的发现和认识作出的:
发明人发现,最近开发出来的内化RGD多肽(iRGD,CRGDK/RGPD/EC),是一种肿瘤靶向和细胞穿透的环肽,可通过依赖于神经肽-1的、肿瘤特异的方式增加抗癌药进入血管外肿瘤组织的能力,从而增强联用抗癌药的疗效。不过,iRGD在临床上却因为很容易水解、半衰期太短很难发挥作用,而iRGD调节的高分子偶联药物却可以通过增强药物在肿瘤部位的富集和穿透性来显著提高肿瘤治疗的效果。为此,发明人提供了一种聚乙二醇偶联药物增效剂,发明人将iRGD通过特殊的化学合成方法连接在聚乙二醇高分子载体上,合成聚乙二醇偶联iRGD,其经血液循环运输到肿瘤部位,在与抗癌药联用时,iRGD在肿瘤微环境中可以被降解出来,增强抗癌药的疗效。
在本发明的第一方面,本发明提供了式(I)所示的聚乙二醇偶联药物增效剂或其药学上可接受的盐,
其中:
PEG1为单臂聚乙二醇链段,PEG1通过羰基与L1相连或者PEG1的末端带有氨基或活化的氨基,PEG1的数均分子量为5k-40k,优选为5k-10k或10k-40k,更优选为10k;
Y1、Y0各自独立地选自 r1为1、2、3、4、5或6,r1优选为1、2、3或4,r1更优选为3或4,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2;
P为-LV-T;
LV选自 各r0独立地为1、2、3、4、5或6,各r0独立地优选为3、4、5或6,各r0独立地更优选为5或6,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2;
在本发明的第二方面,本发明提供了式(I’)所示的聚乙二醇偶联药物增效剂或其药学上可接受的盐,
其中:
PEG1为单臂聚乙二醇链段,PEG1的末端带有氨基或活化的氨基,PEG1的数均分子量为5k-40k,优选为5k-10k或10k-40k,更优选为10k;
Y1、Y0各自独立地选自 r1为1、2、3、4、5或6,r1优选为1、2、3或4,r1更优选为3或4,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2;
P为-LV-T;
LV选自各r0独立地为1、2、3、4、5或6,各r0独立地优选为3、4、5或6,各r0独立地更优选为5或6,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2;
在本发明的第三方面,本发明提供了聚乙二醇偶联药物增效剂或其药学上可接受的盐,其中,所述聚乙二醇偶联药物增效剂选自:
在本发明的第四方面,本发明提供了制备前述的聚乙二醇偶联药物增效剂或其药学上可接受的盐的方法,其包括:
M1、L1、Y1、Y0如前所述,
Pro2为羧基的保护基,优选地,Pro2为苄氧基,
Pro1为氨基或羧基的保护基,优选地,Pro1为氨基的保护基时,Pro1为叔丁氧羰基,优选地,Pro1为羧基的保护基时,Pro1为叔丁氧基;
在本发明的第五方面,本发明提供了中间体,其用于制备前述聚乙二醇偶联药物增效剂或其药学上可接受的盐,所述中间体选自以下:
在本发明的第六方面,本发明提供了组合物,其包含前述聚乙二醇偶联药物增效剂或其药学上可接受的盐。
在一些实施方案中,所述组合物还包含一种或多种药学上可接受的辅料,例如载体和/或赋形剂。所述载体和/或赋形剂包括但不限于:离子交换剂,氧化铝,硬脂酸铝,卵磷脂,血清蛋白如人血清蛋白,缓冲物质如磷酸盐,甘油,山梨酸,山梨酸钾,饱和植物脂肪酸的部分甘油酯混合物,水,盐或电解质,如硫酸鱼精蛋白,磷酸氢二钠,磷酸氢钾,氯化钠,锌盐,胶态氧化硅,三硅酸镁,聚乙烯吡咯烷酮,纤维素物质,聚乙二醇,羧甲基纤维素钠,聚丙烯酸酯,蜂蜡,聚乙烯-聚氧丙烯嵌段聚合物和羊毛脂。
所述组合物可以制成药学上可接受的任一剂型。所述组合物还可以以任何合适的给药方式,例如口服、肠胃外、直肠或经肺给药等方式施用于需要这种治疗的个体。用于口服给药时,所述组合物可制成常规的固体制剂,如片剂、胶囊剂、丸剂、颗粒剂等;也可制成口服液体制剂,如口服溶液剂、口服混悬剂、糖浆剂等。制成口服制剂时,可以加入适宜的填充剂、粘合剂、崩解剂、润滑剂等。用于肠胃外给药时,所述组合物可制成注射剂,包括注射液、注射用无菌粉末与注射用浓溶液。制成注射剂时,可采用现有制药领域中的常规方法生产,配制注射剂时,可以不加入附加剂,也可根据药物的性质加入适宜的附加剂。用于直肠给药时,所述组合物可制成栓剂等。用于经肺给药时,所述组合物可制成吸入剂或喷雾剂等。优选地,本发明的组合物可以被制成注射剂,例如注射液。可选地,以生理盐水作为所述注射液的载体。
在一些实施方案中,所述组合物还包含抗癌药物。
在一些实施方案中,所述抗癌药物为式(A)所示的聚乙二醇偶联药物或其药学上可接受的盐,
其中:
j为3或4;
PEG2为单臂聚乙二醇链段,PEG2通过羰基与L2相连或者PEG2的末端带有氨基或活化的氨基,PEG2的数均分子量为5k-40k,优选为5k-10k或10k-40k,更优选为5k;
Z2、Z1、Z0各自独立地为r1为1、2、3、4、5或6,r1优选为1、2、3或4,r1更优选为3或4,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2,
Q为N-AC;
AC为SB7、NPB、SN38、LPT、PCB、DOX、PTX或AXT,优选为PTX或SN38。
在一些实施方案中,所述聚乙二醇偶联药物选自:
在本发明的第七方面,本发明提供了前述的聚乙二醇偶联药物增效剂或其药学上可接受的盐或者前述的组合物在制备药物中的用途,所述药物用于增强治疗和/或预防疾病的疗效。
在一些实施方案中,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
在本发明的第八方面,本发明提供了增强治疗和/或预防疾病的疗效的方法,其包括对有此需要的个体给予有效量的前述的聚乙二醇偶联药物增效剂或其药学上可接受的盐或者前述的组合物。
在一些实施方案中,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
在本发明的第九方面,本发明提供了前述的聚乙二醇偶联药物增效剂或其药学上可接受的盐或者前述的组合物,其用于增强治疗和/或预防疾病的疗效。
在一些实施方案中,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
在本发明的第十方面,本发明提供了前述的组合物(包含抗癌药物)在制备治疗和/或预防疾病的药物中的用途,所述疾病为前述的抗癌药物所治疗的疾病。
在一些实施方案中,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
在本发明的第十一方面,本发明提供了治疗和/或预防疾病的方法,其包括对有此需要的个体给予有效量的前述的组合物(包含抗癌药物),所述疾病为前述的抗癌药物所治疗的疾病。可调整给药方案以提供最佳所需响应。例如,可给药单次推注,可随时间给药数个分剂量,或可如治疗情况的急需所表明而按比例减少或增加剂量。要注意,剂量值可随要减轻的病况的类型及严重性而变化,且可包括单次或多次剂量。要进一步理解,对于任何特定个体,具体的给药方案应根据个体需要及给药组合物或监督组合物的给药的人员的专业判断来随时间调整。
在一些实施方案中,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
在本发明的第十二方面,本发明提供了前述的组合物(包含抗癌药物),其用于治疗和/或预防疾病,所述疾病为前述的抗癌药物所治疗的疾病。
在一些实施方案中,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
本发明中,癌症是指细胞增殖性疾病状态,包括但不限于:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤等,包括前述癌症的转移。
本发明中,“个体”包括人或非人动物。示例性人个体包括患有疾病(例如本文所述的疾病)的人个体(称为患者)或正常个体。本发明中,“非人动物”包括所有脊椎动物,例如非哺乳动物(例如鸟类、两栖动物、爬行动物)和哺乳动物,例如非人灵长类、家畜和/或驯化动物(例如绵羊、犬、猫、奶牛、猪等)。
如本文中所使用的,术语“有效量”指被给药后会在一定程度上缓解所治疗病症的一或多种症状的化合物的量。
如本文中所使用,术语“治疗”意指逆转、减轻、抑制这样的术语所应用的病症或病况或者这样的病症或病况的一或多种症状的进展,或预防这样的病症或病况或者这样的病症或病况的一或多种症状。
本发明的聚乙二醇偶联药物增效剂,以氨基酸或多肽等为连接链,以带有氨基的二羧酸或多羧酸(例如带有两个羧基的天然氨基酸)或者带有二氨基或多氨基的羧酸(例如带有两个氨基的天然氨基酸)或者多羧酸为连接桥,通过形成酰胺键将多个PPT-iRGD或MI-AH-PPT-iRGD偶联在一起。在某些实施方案中,活化的PEG通过羧基与主链上的氨基发生反应,形成酰胺键。在某些实施方案中,PEG通过末端的氨基与主链上的羧基发生反应,形成酰胺键。在某些实施方案中,PEG的分子量包含其末端的氨基(即带有活性基团的PEG衍生物)。
本发明的聚乙二醇偶联药物,以氨基酸或多肽等为连接链,以带有氨基的二羧酸或多羧酸(例如带有两个羧基的天然氨基酸)或者带有二氨基或多氨基的羧酸(例如带有两个氨基的天然氨基酸)或者多羧酸为连接桥,通过形成酰胺键将多个相同或不同的药物分子偶联在一起。药物的种类、比例和载药量可以调节。在某些实施方案中,活化的PEG通过羧基与主链上的氨基发生反应,形成酰胺键。在某些实施方案中,PEG的分子量包含其末端的氨基(即带有活性基团的PEG衍生物)。
本发明的聚乙二醇偶联药物中,适于与聚乙二醇偶联的活性成分可以是带有至少一个氨基、羟基、羧基或者酰基的药物分子,例如带有至少一个氨基、羟基、羧基或者酰基的具有抗肿瘤活性的药物分子,例如SB7、NPB、SN38、LPT、PCB、DOX、PTX或AXT,其代表的含义如下:
缩写 | 名称 | CAS号或结构式 |
LPT | 拉帕替尼 | 231277-92-2 |
PCB | 帕布惜利布 | 571190-30-2 |
SB7 | SB-743921 | 940929-33-9 |
NPB | Niraparib(MK-4827) | 1038915-60-4 |
SN38 | 7-乙基-10-羟基喜树碱 | 86639-52-3 |
DOX | 阿霉素 | 23214-92-8 |
PTX | 紫杉醇 | 33069-62-4 |
AXT | Axitinib | 319460-85-0 |
MI-AH-PPT-iRGD的结构式为MI-AH-PPT-iRGD与聚乙二醇偶联药物增效剂整体结构的其他部分的连接位点为马来酰亚胺基团即所示位置。在一些实施方案中,MI-AH-PPT-iRGD在马来酰亚胺基团上与另外的巯基进行加成连接。
如本文中所使用,“PEG”为聚乙二醇的缩写,是指重复单元为-CH2CH2O-的均聚物,包括单臂聚乙二醇、多臂聚乙二醇及其衍生物,例如端基带有氨基或羧基等反应官能团的衍生物。本发明的结构式中,聚乙二醇重复单元下角标的字母n代表聚乙二醇的聚合度。
如本文中所使用,除非以其他方式明确指出,在本文中通篇采用的描述方式“各…独立地为/选自”和“…和…各自独立地为/选自”可以互换,均应做广义理解,其既可以是指在不同基团中,相同符号之间所表达的具体选项之间互相不影响,也可以表示在相同的基团中,相同符号之间所表达的具体选项之间互相不影响。
如本文中所使用,本发明的化合物的“药学上可接受的盐”包括化合物的酸加成盐及碱加成盐。例如盐酸盐、六氟磷酸盐、葡甲胺盐等。
附图说明
图1表示本发明实施例的各组肿瘤增长趋势示意图。
图2表示本发明实施例的各组肿瘤重量抑制率示意图。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
实施例中各缩写的含义如下:
部分原料的来源和结构如下:
M-NH2-10K.HCl
键凯,mPEG-CH2CH2-NH2HCl
M-NH2-5K.HCl
键凯,mPEG-CH2CH2-NH2HCl
M-SCM-5K
M-SCM-10K
下面结合具体的实施例对本发明进行进一步的解释说明。
实施例1化合物的制备
45-164的合成:
45-114
称取Boc-L-Lys(Fmoc)-OH(20g,42.6857mmol,购于阿拉丁)、Gly-OBn(14.4g,42.6857mmol,购于innochem)、HBTU(24g,64.0286mmol)、HOBT(8.65g,64.0286mmol)投入500mL反应瓶中,加入DMF(40mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(31.7mL,192.085mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,蒸干得产品26克。
45-115
称取化合物45-114(26g,42.6857mmol),加入二氯甲烷(20mL),再加入TFA(14mL,190.2855mmol),超声溶解,搅拌反应。反应结束,反应液浓缩,再用乙酸乙酯(100mL)溶解,加饱和氯化钠溶液,分离有机相,水相用乙酸乙酯萃取3次(50mL×3),直至水相无产品,合并有机相,再用饱和食盐水清洗一次(50mL),浓缩蒸干得产品22g。
45-124
称取Boc-L-Lys(Boc)-OH(7.3g,21.334mmol,购于Aladdin)、45-115(11g,21.334mmol)、HBTU(12.1363g,32.0016mmol)、HOBT(4.3241g,32.0016mmol)投入500mL反应瓶中,加入DMF(80mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(15mL,96.003mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,干法上样,柱层析,用50%-100%乙酸乙酯/石油醚梯度洗脱得产品15克,产率83%。
45-126
称取化合物45-124(15g,17.7725mmol),加入二氯甲烷(30mL),再加入TFA(39mL,533.1754mmol),超声溶解,搅拌反应。反应结束,反应液浓缩,再用乙酸乙酯(100mL)溶解,加饱和碳酸氢钠溶液至水相显碱性,分离有机相,水相用乙酸乙酯萃取3次(150mL×3),直至水相无产品,合并有机相,再用饱和食盐水清洗一次(150mL),浓缩蒸干得产品11.44g。
45-127
称取Boc-L-Lys(Boc)-OH(13.022g,37.5911mmol)、45-126(11.4g,17.0868mmol)、HBTU(19.5538g,51.5604mmol)、HOBT(6.9668g,51.5604mmol)投入500mL反应瓶中,加入DMF(80mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(25.4mL,153.7812mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,干法上样,柱层析,用1%-55甲醇/二氯甲烷梯度洗脱得产品18克,产率81%。
45-135
取反应物45-127(1.1g,0.8458mmol)置于250mL烧瓶中,加DMF溶液(50mL),加入吗啉(1.4745mL,16.9155mmoL),常温搅拌反应,3小时后,反应结束。饱和食盐水(150mL)和乙酸乙酯(200mL),分离有机相,水相用乙酸乙酯萃取3次(150mL×3),水相中无产品,合并有机相,用饱和食盐水清洗2次(150mL×2),有机相蒸干得产品0.912克。
45-57
称季戊四醇(10g,73.4484mmol)投500mL两颈反应瓶中,加四氢呋喃(20mL)超声均匀,置于0℃条件下搅拌,通入氮气保护后,加叔丁醇钾(352mL,352.55mmol),℃下搅拌2小时后,加入溴乙酸苄酯(55mL,352.55mmol),再搅拌3小时后移至常温下反应。反应结束,用纯水与乙酸乙酯萃取处理反应液,浓缩有机相,干法上样,柱层析。用1%-2%乙酸乙酯/石油醚梯度洗脱得产品15g,产率28%。
45-64
称45-57(0.76g,1.0538mmol)与10%Pd/C(100mg)投入氢化反应釜中,缓慢加入DMF(30mL)搅拌溶解,通入氢气(300psi),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得45-64的DMF溶液,直接投下一步反应。
45-136
称取45-135(0.9121g,0.8458mmol)、HBTU(0.4009g,1.0572mmol)、HOBT(0.1388g,10572mmol)投入250mL反应瓶中,加入45-64(0.1762mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.5242mL,3.1716mmol),-5℃条件下反应过夜。反应结束,在反应液中加纯水,抽滤,干法上样,柱层析。用1%-5%甲醇/二氯甲烷洗脱得产品0.4g,产率50%。
1H-NMR(600MHz,DMSO-d6)δ8.37-8.33(m,2H),7.98–7.81(m,13H),7.72-7.70(m,9H),7.63-7.62(m,1H),7.40-7.30(m,24H),6.89-6.86(m,2H),6.74-6.69(m,6H),5.11-5.10(m,4H),4.55-4.54(m,3H),4.24-4.16(m,6H),3.99–3.78(m,12H),3.65-3.62(m,6H),3.37-3.33(s,48H),3.08–2.82(m,42H),2.71-2.68(m,25H),2.57-2.53(m,10H),1.68–1.14(m,161H).
45-138
称45-136(0.35g,0.0759mmol)与10%Pd/C(75mg)投入氢化反应釜中,缓慢加入DMF(50mL)搅拌溶解,通入氢气(20psi),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得产品的DMF溶液,直接投下一步反应。
45-139
称取M-NH2HCl-10K(3.3679g,0.3188mmol,购于键凯)、HBTU(0.1727g,0.4554mmol)、HOBT(0.0615g,0.4554mmol)投入250mL反应瓶中,加入45-138(0.0667mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.1766mL,1.3662mmol),-5℃条件下反应1小时后移至常温下低速避光反应。反应结束,在反应液中加甲基叔丁基醚,抽滤,干法上样,柱层析。用5%-8%甲醇/二氯甲烷洗脱得产品1.2g。
1H-NMR(600MHz,DMSO-d6)δ9.04-9.02(m,2H),7.96-7.92(m,8H),7.89-7.77(m,10H),7.37-7.34(m,12H),6.78-6.61(m,9H),4.53-4.52(m,4H),3.87-3.85(m,9H),3.64-3.60(m,46H),3.51-3.49(m,3683H),3.41-3.39(m,18H),3.24-3.23(m,6H),2.90-2.88(m,12H),2.74-2.72(m,14H),2.62-2.60(m,29H),2.39-2.37(m,8H),1.38–1.34(m,85H),1.27–1.20(m,84H).
45-154
称取化合物45-139(0.4g,0.0146mmol),加入二氯甲烷(10mL),再加入TFA(0.25mL,3.4983mol),超声溶解,搅拌反应。反应结束,在反应液中加甲醇(30mL),加过量碳酸钾,搅拌30分钟,抽滤,滤液中加硅胶粉蒸干,上样,柱层析。用6%-50%甲醇/二氯甲烷梯度洗脱得产品0.2g,产率54%。
45-156
称取45-154(0.2g,0.0044mmol)、6-马来酰亚胺基己酸(0.0189g,0.0895mmol)、HBTU(0.0400g,0.1056mmol)、HOBT(0.0143g,0.1056mmol)投入250mL反应瓶中,DMF溶液溶解,-5℃条件下避光搅拌30分钟后。缓慢滴加DIEA(0.0523mL,0.3168mmol),-5℃条件下反应1小时后移至常温下避光反应。反应结束,在反应液中加甲基叔丁基醚倾倒多次得产品0.1g,产率50%。
45-164
称取45-156(0.4477g,0.0094mmol)、PPT-iRGD(0.3g,0.1874mmol,购于丹港生物科技)、投入250mL反应瓶中,加DMSO(50mL)溶液溶解,40℃条件下避光搅拌2天,常温搅拌3天。反应结束,在反应液中加甲基叔丁基醚,倾倒,固体不用10%甲醇/二氯甲烷溶解,加硅胶粉(5g),干法上样,柱层析。用5%-10%甲醇/二氯甲烷洗脱得产品0.3g,产率44%。
1H-NMR(600MHz,DMSO-d6)δ9.13-9.12(m,6H),8.40-7.83(m,255H),7.40-7.26(m,94H),7.13-7.12(m,6H),7.01–6.88(m,3H),6.70-6.68(m,4H),4.54-4.52(m,52H),4.26-4.24(m,83H),3.78-3.76(m,131H),3.51-3.49(m,4200H),3.09-3.07(m,178H),2.89-2.86(m,225H),2.71-2.69(m,212H),2.37-2.35(m,22H),2.16-1.97(m,52H),1.81-1.76(m,102H),1.55-1.52(m,174H),1.33-1.28(m,288H),0.85-0.81(m,192H).
化合物49-166的合成(抗癌药)
称取Boc-Glu-OH(5.0g,20.22mmol,购于阿拉丁)、H-Glu(OBzl)-OBzl·TsOH(21.2g,42.46mmol,购于Ark Pharm)、HOBT(8g,60.66mmol)、HBTU(23g,60.66mmol)投入250mL反应瓶中,加DMF溶液(80mL)溶解,超声使反应物完全溶解,-5℃条件下搅拌30分钟,缓慢滴加DIEA(30mL,181mmol),低温反应至结束。反应结束后,取出反应液加入去离子水(100mL),用乙酸乙酯萃取多次(100mL×3),合并有机相,有机相加入饱和氯化钠溶液(100mL)清洗两次,最后浓缩蒸干。干法上样,柱层析,用40%乙酸乙酯/石油醚-50%乙酸乙酯/石油醚梯度洗脱收集产品,浓缩蒸干。
39-84
取39-80(19.2mmol),加入二氯甲烷(5mL),再加入TFA(14mL,192mmol),超声使完全溶解,用磨口玻璃塞,常温搅拌反应。反应结束后,取出反应液加入饱和碳酸氢钠溶液(300mL),用乙酸乙酯萃取多次(100mL×3),合并有机相,有机相加入饱和氯化钠溶液(100mL)清洗两次,最后浓缩蒸干。
47-96
将7-乙基-10-羟基喜树碱(15.00g,38.23mmol,简写为SN38)置于1000ml圆底烧瓶中,加入二氯甲烷150ml使之溶解,加入叔丁基二苯基氯硅烷(59.64ml,229.36mmol,购于韶远)、三乙胺(31.88ml,229.36mmol),反应在37℃油浴下搅拌过夜。反应结束后,将反应液蒸至粘稠状,加入正己烷(150ml)将产物沉降至固体,抽滤、烘干,得到产品(23.15g,96%)。
47-97
将47-96(23.15g,36.70mmol)、Boc-Gly-OH(8.71g,49.70mmol,购于阿拉丁)、DMAP(0.94g,7.65mmol)置于1000mL圆底烧瓶中,然后加入二氯甲烷(150mL),使其溶解,将混合液置于0℃条件下搅拌30分钟。然后分三次共加入DCC(39.41g,191.15mmol),每次加入DCC间隔时间为30min,结束后0℃下反应2小时,然后将反应装置放到室温条件下搅拌过夜反应。反应结束后,加入正己烷(200mL)和石油醚(50mL)沉降,重复3次,过滤得到固体产物,放入真空箱中干燥,得到产品(27.53g,94%)。
47-98
将47-97(27.53g,34.50mmol)置于1000ml圆底烧瓶中,加入二氯甲烷(50ml)溶解后,加入三氟乙酸(28.40ml,382.30mmol),将反应至于室温下进行。反应结束后,取出反应液加入去离子水(200mL),用乙酸乙酯(100mL×3)萃取,合并有机相,有机相加入饱和氯化钠溶液(200mL×2)清洗,浓缩,加入硅胶粉,蒸干至粉末状,柱层析,用(1%-3%CH3OH,其余CH2Cl2)梯度洗脱,收集浓缩,得到产品(16.98g,72%)。
29-242
将Fmoc-Lys(Boc)-OH(5.0g,10.6714mmol,购于阿拉丁)、H-Gly-OBn(3.7802g,11.2050mmol,购于innochem)、HBTU(6.0705g,16.0072mmol)、HOBT(2.1630g,16.0072mmol)加入到500ml烧瓶中,加入DMF(50mL)使其溶解,置于0摄氏度下搅拌反应30分钟。再缓慢滴加DIEA(7.9371mL,48.0215mmol),继续在0摄氏度下搅拌反应过夜。反应结束后,取出反应液加入去离子水(200mL),用乙酸乙酯(100mL×3)萃取,合并有机相,有机相加入饱和氯化钠溶液(200mL)清洗两次,浓缩蒸干,真空箱干燥,得到粗产品。
29-243
将29-242(6.57g,10.6714mmol)加入500ml烧瓶中,加入适量的二氯甲烷和TFA(7.9248mL,106.714mmol)使之溶解,反应在室温下搅拌过夜。反应结束后,取出反应液蒸至油状,加饱和碳酸氢钠溶液调节PH至碱性,再用乙酸乙酯(100mL×3)萃取,合并有机相,有机相加入饱和氯化钠溶液(200mL)清洗两次,浓缩蒸干,真空箱干燥,得到粗产品。
29-245
将Boc-Lys(Boc)-OH(4.2805g,11.7385mmol,购于Ark Pharm)、29-243(5.50g,10.6714mmol)、HBTU(6.0705g,16.0072mmol)、HOBT(2.1630g、16.0072mmol)加入到500ml烧瓶中,加入DMF(50mL)使其溶解,置于0摄氏度下搅拌反应30分钟。再缓慢滴加DIEA(7.9371mL,48.0215mmol),继续在0摄氏度下反应过夜。反应结束后,取出反应液加入去离子水(200mL),用乙酸乙酯(100mL×3)萃取,合并有机相,有机相加入饱和氯化钠溶液(200mL)清洗两次,浓缩蒸干,真空箱干燥,得到粗产品。
29-246
将吗啉(9.24mL,106.714mmol)和DMF(10mL)加入到装有29-245(9.0g,10.6714mmol)的500ml烧瓶中,使之溶解,反应在室温下搅拌1小时。反应结束后,取出反应液加入去离子水(200mL),用乙酸乙酯(100mL×3)萃取,合并有机相,有机相加入饱和氯化钠溶液(200mL)清洗两次,浓缩,加入硅胶粉,蒸干至粉末状,柱层析,用(1%氨水,4%-5%甲醇,其余二氯甲烷)梯度洗脱,收集浓缩,得到产品29-246:3.7g,产率56%。
29-248
将38-120(0.39g,1.0966mmol)、29-246(3.0g,4.8249mmol)、HBTU(2.4951g,6.5795mmol)、HOBT(0.8891g,6.5795mmol)加入到500ml烧瓶中,加入DMF(50mL)使其溶解,置于-5摄氏度下搅拌反应30分钟。再缓慢滴加DIEA(3.2624mL,19.7384mmol),在-5摄氏度下搅拌反应1小时后,移至室温下搅拌过夜。反应结束后,取出反应液加入去离子水(200mL),用乙酸乙酯(100mL×3)萃取,合并有机相,有机相加入饱和氯化钠溶液(200mL)清洗两次,浓缩,加入硅胶粉,蒸干至粉末状,柱层析,用(50%-80%乙酸乙酯,其余石油醚)梯度洗脱,收集浓缩,得到产品(1.6g,53%)。
49-79
将29-248(0.52g,0.1878mmol)和10%Pd/C(0.0,5g)投入到氢化反应釜中,然后加入DMF(30mL)使其溶解,封闭氢化反应装置,进行三抽三充后使氢化反应装置上的压力读数为0.18MPa,然后在常温下过夜反应。反应结束,反应液用硅藻土过滤,滤饼用DMF(20mLⅹ3)清洗,得到产品的DMF溶液,作为下一部反应原料。
49-80
将49-79(0.45g,0.1878mmol)、M-NH2HCl-5K(4.91g,0.9389mmol,购于键凯)、HBTU(0.43g,1.1237mmol)、HOBT(0.15g,1.1267mmol)加入到500ml烧瓶中,加入DMF(60mL)使其溶解,置于-5摄氏度下搅拌反应30分钟。再缓慢滴加DIEA(0.56mL,3.3780mmol),在-5摄氏度下搅拌反应1小时后,移至室温下低速避光搅拌三天。反应结束,用正己烷(100mL)震荡,倒掉上清液,重复上述操作三次,再加甲基叔丁基醚(80mL)和少量正己烷(10mL)震荡,倒掉上清液,重复三次,反应液中粉末状固体析出,抽滤,滤饼用甲基叔丁基醚(40mL x 3)清洗,收集滤饼,然后用甲醇/二氯甲烷(1:4)溶液(100mL)溶解,加入硅胶粉(20g),蒸干至粉末状,干法上样,柱层析,用1%氨水和3%-7%甲醇的二氯甲烷混合溶液梯度洗脱,收集浓缩,真空烘箱干燥,得到产品(3.2g,73.73%)。
49-153
将49-80(3.2g,0.1383mmol)加入250mL烧瓶中,加入二氯甲烷(5mL)和TFA(0.82mL,11.0640mmol)使之溶解,反应在室温下低速避光搅拌过夜。反应结束,用旋转蒸发仪将反应液蒸至油状,再加入甲基叔丁基醚(60mL),反应液中粉末状固体析出,抽滤,滤饼用甲基叔丁基醚(40mL x 3)清洗,收集滤饼,然后用甲醇/二氯甲烷(1:4)溶液(100mL)溶解,加入硅胶粉(20g),蒸干至粉末状,干法上样,柱层析,用3%-12%甲醇的二氯甲烷混合溶液梯度洗脱,收集浓缩,真空烘箱干燥,得到产品(1.74g,56.35%)。
49-157
将39-84(5.16g,6.7433mmol)、单叔丁基琥珀酸(1.40g,8.0920mmol,购于Accela)、HBTU(3.84g,10.1149mmol)、HOBT(1.36g,10.1149mmol)加入500ml烧瓶中,加入DMF(50mL)使其溶解,置于-5摄氏度下搅拌反应30分钟。再缓慢滴加DIEA(10.03mL,60.6897mmol),在-5摄氏度下搅拌反应1小时后,移至室温下搅拌过夜。反应结束后,取出反应液加入去离子水(200mL),用乙酸乙酯(100mL×3)萃取,合并有机相,有机相加入饱和氯化钠溶液(200mL)清洗两次,浓缩,加入硅胶粉,蒸干至粉末状,柱层析,用(50%-90%乙酸乙酯,其余石油醚)梯度洗脱,收集浓缩,得到产品(5.66g,90.99%)。
49-158
将49-157(2.8g,3.0367mmol)和10%Pd/c(0.08g)投入到氢化反应釜中,然后加入DMF(30mL)使其溶解,封闭氢化反应装置,进行三抽三充后使氢化反应装置上的压力读数为0.18MPa,然后在常温下过夜反应。反应结束,反应液用硅藻土过滤,滤饼用DMF(20mLⅹ3)清洗,得到产品的DMF溶液,作为下一部反应原料。
49-159
将49-158(1.71g,3.0367mmol)、47-98(8.77g,12.7541mmol)、HBTU(6.90g,18.2202mmol)、HOBT(2.46g,18.2202mmol)加入到500ml烧瓶中,加入DMF(60mL)使其溶解,置于-5摄氏度下搅拌反应30分钟。再缓慢滴加DIEA(13mL,78.9542mmol),在-5摄氏度下搅拌反应1小时后,移至室温下搅拌过夜。反应结束,用正己烷(100mL)震荡,倒掉上清液,重复上述操作三次,再加甲基叔丁基醚(80mL)和少量正己烷(10mL)震荡,倒掉上清液,重复三次,反应液中粉末状固体析出,抽滤,滤饼用甲基叔丁基醚(40mL x 3)清洗,收集滤饼,然后用甲醇/二氯甲烷(1:4)溶液(100mL)溶解,加入硅胶粉(60g),蒸干至粉末状,干法上样,柱层析,用3%-7%甲醇的二氯甲烷混合溶液梯度洗脱,收集浓缩,真空烘箱干燥,得到产品(11.3g,超产)。
49-161
将49-159(9.84g,3.0367mmol)加入250mL烧瓶中,加入二氯甲烷(8mL)和TFA(8mL)使之溶解,反应在室温下搅拌过夜。反应结束,用旋转蒸发仪将反应液蒸至油状,再加入甲基叔丁基醚(60mL),反应液中粉末状固体析出,抽滤,滤饼用甲基叔丁基醚(40mL x 3)清洗,收集滤饼,然后用甲醇/二氯甲烷(1:4)溶液(100mL)溶解,加入硅胶粉(60g),蒸干至粉末状,干法上样,柱层析,用1%-4%甲醇的二氯甲烷混合溶液梯度洗脱,收集浓缩,真空烘箱干燥,得到产品(2.7g,27.92%)。
49-162
将49-153(1.19g,0.0535mmol)、49-161(1.5g,0.4710mmol)、HBTU(0.24g,0.6422mmol)、HOBT(0.08g,0.6422mmol)加入到500ml烧瓶中,加入DMF(60mL)使其溶解,置于-5摄氏度下搅拌反应30分钟。再缓慢滴加DIEA(0.60mL,3.6395mmol),在-5摄氏度下搅拌反应1小时后,移至室温下低速避光搅拌过夜。反应结束,加入正己烷(100mL)震荡,倒掉上清液,重复上述操作三次,再加甲基叔丁基醚(80mL)和少量正己烷(10mL)震荡,倒掉上清液,重复三次,反应液中粉末状固体析出,抽滤,滤饼用甲基叔丁基醚(40mL x 3)清洗,收集滤饼,然后用甲醇/二氯甲烷(1:4)溶液(100mL)溶解,加入硅胶粉(20g),蒸干至粉末状,干法上样,柱层析,用3%-15%甲醇的二氯甲烷混合溶液梯度洗脱,收集浓缩,真空烘箱干燥,得到产品(0.95g,37.25%)。
49-166
向装有49-162(0.95g,0.0199mmol)的500ml烧瓶中,加入THF(10ml)和稀盐酸(10ml,0.05mmol/L),超声使之溶解,再加入TBAF(0.5g,1.9133mmol),反应在室温下避光搅拌3小时。反应结束后,将反应液蒸干,用DMF(5ml)溶解,再用异丙醇沉降,重复三次;再用无水乙醇和少量二氯甲烷溶解,加甲基叔丁基醚沉降,重复三次,收集固体,真空箱干燥,得到产品(0.75g,93.75%)。
1H-NMR(600MHz,DMSO-d6)δ8.44–8.22(m,24H),8.05–7.89(m,46H),7.44–7.27(m,78H),5.53–5.34(m,50H),5.31–5.08(m,52H),4.55–4.44(m,15H),4.29–4.13(m,31H),4.11–3.89(m,71H),3.89–3.80(m,23H),3.78–3.60(m,82H),3.55–3.44(m,1892H),3.11–2.75(m,100H),2.36–2.21(m,28H),2.20–1.97(m,91H),1.61–1.49(m,34H),1.31–1.16(m,136H),0.97–0.91(m,30H),0.90–0.76(m,79H)。
称取Fmoc-Glu-OH(2.974g,8.05mmol,购于阿拉丁)、NH2-Glu-OtBu(5g,16.90mmol,购于innochem)、HBTU(9.16g,24.15mmol)、HOBT(3.26g,24.15mmol)投入500mL反应瓶中,加入DMF(10mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(11.97mL,72.45mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,加无水硫酸钠干燥,抽滤,浓缩有机相,蒸干得产品7克。
38-139
取反应物38-137(6.9g,8.05mmol)置于250mL烧瓶中,加DMF溶液(50mL),加入吗啉(14mL,161mmoL),常温搅拌反应,3小时后,反应结束。饱和食盐水(150mL)和乙酸乙酯(200mL),分离有机相,水相用乙酸乙酯萃取3次(150mL×3),水相中无产品,合并有机相,用饱和食盐水清洗2次(150mL×2),有机相蒸干得产品5克。
38-142
称取38-139(5g,8.05mmol),投入250mL反应瓶中,加DMF(50mL)溶解,在-5℃搅拌条件下加入DIEA(6.6526mL,40.25mmol),反应30分钟后快速加入丁二酸酐(2.4137g,24.15,mmol),低温反应结束,反应结束,用去离子水与乙酸乙酯萃取处理,有机相用饱和食盐水清洗2次,浓缩有机相,蒸干得产品5g,产率86%。
38-143
称取38-142(5g,6.8506mmol)、45-115(3.53g,6.8506mmol)、HBTU(3.897g,10.2759mmol)、HOBT(1.3885g,10.2759mmol)投入500mL反应瓶中,加入DMF(10mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(5.0952mL,30.8277mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,蒸干得产品7克,产率83.3%。
38-144
取反应物38-143(7g,5.7029mmol)置于250mL烧瓶中,加DMF溶液(50mL),加入吗啉(9..9368mL,114.0585mmol),常温搅拌反应,3小时后,反应结束。饱和食盐水(150mL)和乙酸乙酯(200mL),分离有机相,水相用乙酸乙酯萃取3次(150mL×3),水相中无产品,合并有机相,用饱和食盐水清洗2次(150mL×2),有机相蒸干,柱层析,用1%-4%甲醇/二氯甲烷梯度洗脱得产品4克,产率70%。
21-221
称赤藓醇(4.5g,36.849mmol)投500mL两颈反应瓶中,加四氢呋喃(60mL)超声均匀,置于0℃条件下搅拌,通入氮气保护后,加叔丁醇钾(200mL,184.245mmol),0℃下搅拌2小时后,加入溴乙酸苄酯(29.187mL,184.245mmol),再搅拌3小时后移至常温下反应。反应结束,用纯水与乙酸乙酯萃取处理反应液,浓缩有机相,干法上样,柱层析。用1%-2%乙酸乙酯/石油醚梯度洗脱得产品5g,产率20%。
38-145
称21-221(0.64g,0.9793mmol)与10%Pd/C(100mg)投入氢化反应釜中,缓慢加入DMF(30mL)搅拌溶解,通入氢气(300psi),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得产品的DMF溶液,直接投下一步反应。
38-146
称取38-144(4g,3.9793mmol)、HBTU(9.0546g,23.8758mmol)、HOBT(3.2261g,23.8758mmol)投入250mL反应瓶中,加入38-145(0.9043mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(11.8354mL,71.6274mmol),-5℃条件下反应过夜。反应结束,在反应液中加纯水,抽滤,干法上样,柱层析。用1%-5%甲醇/二氯甲烷洗脱得产品2.5g,产率74.34%。
38-148
称38-146(0.29g,0.0676mmol)与10%Pd/C(50mg)投入氢化反应釜中,缓慢加入DMF(30mL)搅拌溶解,通入氢气(300psi),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得产品的DMF溶液,直接投下一步反应。
38-149
称取N-Boc-乙二胺(0.0656g,0.4092mmol)、HBTU(0.2116g,0.5580mmol)、HOBT(0.0754g,0.5580mmol)投入250mL反应瓶中,加入38-148(0.0930mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.27mL,1.67mmol),-5℃条件下反应过夜。反应结束,在反应液中加纯水,抽滤,干法上样,柱层析。用1%-5%甲醇/二氯甲烷洗脱得产品0.2g,产率50%。
38-152
称取化合物38-149(0.2g,0.0443mmol),加入二氯甲烷(20mL),再加入TFA(2mL),超声溶解,搅拌反应。反应结束,加甲基叔丁基醚与正己烷,抽滤,得产品0.14g,产率100%。
38-153
称取化合物38-152(0.14g,0.1443mmol),加入DMF(20mL)超声溶解,-5℃条件下搅拌20分钟,缓慢加入DIEA(0.29mL,1.772mol),搅拌20分钟后加入M-SCM-10K(2.11g,0.1950mmol),1小时后移至常温下避光低速搅拌7天,反应结束,加甲基叔丁基醚与正己烷,抽滤,滤饼干法上样,柱层析。用1%氨水+5%-25%甲醇/二氯甲烷梯度洗脱得产品1.5g,产率75%。
38-155
称取38-153(1.3g,0.0288mmol)、1-(2-氨基乙基)-1H-吡咯-2,5-二酮盐酸盐(0.0808g,0.5767mmol,购于上海雷祺生物)、HBTU(0.2621g,0.6912mmol)、HOBT(0.0934g,0.6912mmol)投入500mL反应瓶中,加入DMF(10mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.3427mL,2.0736mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,蒸干得产品1.3克。
38-161
称取38-155(1.3g,0.0276mmol)、PPT-iRGD(0.8847g,0.5527mmol,购于丹港生物科技)、投入250mL反应瓶中,加DMSO(50mL)溶液溶解,40℃条件下避光搅拌2天,常温搅拌3天。反应结束,在反应液中加甲基叔丁基醚,倾倒,固体不用10%甲醇/二氯甲烷溶解,加硅胶粉(5g),干法上样,柱层析。用5%-10%甲醇/二氯甲烷洗脱得产品1.2g,产率57.14%。
1H-NMR(600MHz,DMSO-d6)δ9.57–9.13(m,31H),9.09–8.63(m,10H),8.02–7.91(m,50H),7.91–7.80(m,75H),7.79–7.70(m,4H),7.69–7.54(m,2H),7.53–7-48(s,1H),7.45–7.38(s,1H),7.37–7.27(m,2H),7.26–7.19(s,1H),3.82–3.77(m,15H),3.76–3.72(m,13H),3.67–3.63(m,5H),3.62–3.52(m,63H),3.55–3.42(m,3934H),3.15–3.07(m,58H),3.06–3.01(m,44H),2.99–2.95(m,13H),2.94–2.85(m,625H),2.78–2.76(m,6H),2.75–2.70(m,155H),2.69–2.66(m,11H),2.63–2.59(m,4H),2.58–2.53(m,132H),2.52–2.45(m,134H),1.69–1.62(m,11H),1.59–1.49(m,8H),1.42–1.34(m,13H),1.31–1.22(m,460H),1.20–1.10(m,27H)。
38-192的合成:
称1.2-双(2-氨基乙氧基)乙烷(50mL,340.7327mmol,购于Tcl)投入500mL反应瓶中,加二氯甲烷(150mL)溶解,加三乙胺(94.9828mL,681.4654mmol),在搅拌条件下缓慢分批加入(Boc)2O(74.3751g,340.7327mmol),常温搅拌过夜。次日在反应液中直接加入硅胶粉,蒸干,上样,柱层析。用2%-5%甲醇/二氯甲烷梯度洗脱得产品9.3g,产率10%。
38-172
将45-16(8g,11.9225mmol)、6-马来酰亚胺基己酸(2.7701g,13.1147mmol)、HBTU(6.782g,17.8838mmol)、HOBT(2.4166g,17mmol)加入到装有500ml烧瓶中,加入适量DMF(50mL)使其溶解,置于-5摄氏度下避光搅拌30分钟,再缓慢滴加DIEA(8.8676mL,53.6512mmol),在-5摄氏度下避光搅拌反应1小时后,移至室温下避光搅拌过夜。反应结束,用乙酸乙酯与饱和食盐水萃取处理,浓缩,蒸干有机相得到产品10g。
38-179
将38-172(10g,22.649mmol)加入250mL烧瓶中,加入二氯甲烷(15mL)和TFA(25ml,339.7325mmol)使之溶解,反应在室温下避光搅拌过夜。反应结束,用旋转蒸发仪将反应液蒸至油状,再加入甲基叔丁基醚(60mL),反应液中粉末状固体析出,抽滤,收集滤饼,然后用甲醇/二氯甲烷(1:4)溶液(100mL)溶解,加入硅胶粉(20g),蒸干至粉末状,干法上样,柱层析,用3%-10%甲醇的二氯甲烷混合溶液梯度洗脱,收集浓缩,真空烘箱干燥,得到产品3g,产率38.96%。
38-191
称取38-153(1g,0.0221mmol)、38-179(0.1508g,0.442mmol)、HBTU(0.2012g,0.5304mmol)、HOBT(0.0717g,1.5912mmol)投入500mL反应瓶中,加入DMF(10mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.2630mL,1.5912mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,蒸干得产品1克。
38-192
称取38-191(1g,0.0199mmol)、PPT-iRGD(0.6370g,0.3979mmol)、投入250mL反应瓶中,加DMSO(50mL)溶液溶解,40℃条件下避光搅拌2天,常温搅拌3天。反应结束,在反应液中加甲基叔丁基醚,倾倒,固体不用10%甲醇/二氯甲烷溶解,加硅胶粉(5g),干法上样,柱层析。用5%-10%甲醇/二氯甲烷洗脱得产品0.8g,产率50%。
1H-NMR(600MHz,DMSO-d6)δ8.44-8.33(m,64H),8.25-8.18(m,47H),7.29-7.22(m,144H),4.90-4.79(m,8H),4.66-4.45(m,101H),4.38-4.19(m,194H),3.80-3.71(m,83H),3.55-3.45(m,3843H),3.20-3.04(m,208H),2.94-2.86(m,72H),2.83-2.72(m,153H),2.35-2.31(m,20H),2.06-2.02(m,29H),1.92-1.83(m,189H),1.68-1.42(m,435H),1.30-1.21(m,155H),0.88-0.83(m,192H)。
52-95的合成:
45-114
称取Boc-L-Lys(Fmoc)-OH(20g,42.6857mmol)、Gly-OBn(14.4g,42.6857mmol)、HBTU(24g,64.0286mmol)、HOBT(8.65g,64.0286mmol)投入500mL反应瓶中,加入DMF(40mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(31.7mL,192.085mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,蒸干得产品26克。
45-115
称取化合物45-114(26g,42.6857mmol),加入二氯甲烷(20mL),再加入TFA(14mL,190.2855mmol),超声溶解,搅拌反应。反应结束,反应液浓缩,再用乙酸乙酯(100mL)溶解,加饱和碳酸氢钠溶液至水相显碱性,分离有机相,水相用乙酸乙酯萃取3次(50mL×3),直至水相无产品,合并有机相,再用饱和食盐水清洗一次(50mL),浓缩蒸干得产品22g。
45-124
称取Boc-L-Lys(Boc)-OH(7.3g,21.334mmol)、45-115(11g,21.334mmol)、HBTU(12.1363g,32.0016mmol)、HOBT(4.3241g,32.0016mmol)投入500mL反应瓶中,加入DMF(80mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(15mL,96.003mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,干法上样,柱层析,用50%-100%乙酸乙酯/石油醚梯度洗脱得产品15克,产率83%。
45-126
称取化合物45-124(15g,17.7725mmol),加入二氯甲烷(30mL),再加入TFA(39mL,533.1754mmol),超声溶解,搅拌反应。反应结束,反应液浓缩,再用乙酸乙酯(100mL)溶解,加饱和碳酸氢钠溶液至水相显碱性,分离有机相,水相用乙酸乙酯萃取3次(150mL×3),直至水相无产品,合并有机相,再用饱和食盐水清洗一次(150mL),浓缩蒸干得产品11.44g。
45-127
称取Boc-L-Lys(Boc)-OH(13.022g,37.5911mmol)、45-126(11.4g,17.0868mmol)、HBTU(19.5538g,51.5604mmol)、HOBT(6.9668g,51.5604mmol)投入500mL反应瓶中,加入DMF(80mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(25.4mL,153.7812mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,干法上样,柱层析,用1%-55甲醇/二氯甲烷梯度洗脱得产品18克,产率81%。
45-135
取反应物45-127(1.1g,0.8458mmol)置于250mL烧瓶中,加DMF溶液(50mL),加入吗啉(1.4745mL,16.9155mmoL),常温搅拌反应,3小时后,反应结束。饱和食盐水(150mL)和乙酸乙酯(200mL),分离有机相,水相用乙酸乙酯萃取3次(150mL×3),水相中无产品,合并有机相,用饱和食盐水清洗2次(150mL×2),有机相蒸干得产品0.912克。
21-221
称赤藓醇(4.5g,36.849mmol)投500mL两颈反应瓶中,加四氢呋喃(60mL)超声均匀,置于0℃条件下搅拌,通入氮气保护后,加叔丁醇钾(200mL,184.245mmol),0℃下搅拌2小时后,加入溴乙酸苄酯(29.187mL,184.245mmol),再搅拌3小时后移至常温下反应。反应结束,用纯水与乙酸乙酯萃取处理反应液,浓缩有机相,干法上样,柱层析。用1%-2%乙酸乙酯/石油醚梯度洗脱得产品5g,产率20%。
38-120
称21-221(0.64g,0.9793mmol)与10%Pd/C(100mg)投入氢化反应釜中,缓慢加入DMF(30mL)搅拌溶解,通入氢气(300psi),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得产品的DMF溶液,直接投下一步反应。
52-86
称取45-135(0.5g,0.46mmol)、HBTU(0.22g,0.576mmol)、HOBT(0.08g,0.576mmol)投入250mL反应瓶中,加入38-120(0.096mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.3mL,1.728mmol),-5℃条件下反应过夜。反应结束,在反应液中加纯水,抽滤,干法上样,柱层析。用2%甲醇/二氯甲烷洗脱得产品0.32g,产率50%。
52-88
称52-86(0.32g,0.0694mmol)与10%Pd/C(75mg)投入氢化反应釜中,缓慢加入DMF(50mL)搅拌溶解,通入氢气(2MPa),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得产品的DMF溶液,直接投下一步反应。
52-90
称取M-NH2HCl-10K(3.065g,0.2914mmol)、HBTU(0.1579g,0.4164mmol)、HOBT(0.0562g,0..4164mmol)投入250mL反应瓶中,加入52-88(0.0667mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.257mL,1.5545mmol),-5℃条件下反应1小时后移至常温下低速避光反应。反应结束,在反应液中加甲基叔丁基醚,抽滤,干法上样,柱层析。用5%-6%甲醇/二氯甲烷洗脱得产品1.2g。
52-92
称取化合物52-90(1.5g,0.0325mmol),加入二氯甲烷(10mL),再加入TFA(0.78mL,10.4mol),超声溶解,搅拌反应。反应结束,在反应液中加甲醇(30mL),加过量碳酸钾,搅拌30分钟,抽滤,烘干得产品2g。
52-93
称取52-92(0.0325mmol)、6-马来酰亚胺基己酸(0.137g,0.65mmol)、HBTU(0.295g,0.78mmol)、HOBT(0.105g,0.78mmol)投入250mL反应瓶中,DMF溶液溶解,-5℃条件下避光搅拌30分钟后。缓慢滴加DIEA(0.4mL,2.34mmol),-5℃条件下反应1小时后移至常温下避光反应。反应结束,在反应液中加甲基叔丁基醚倾倒多次得产品1.5g。
52-95
称取52-93(0.0325mmol)、PEPTIDE-iRGD(1.04g,0.65mmol)、投入250mL反应瓶中,加DMSO(50mL)溶液溶解,40℃条件下避光搅拌2天,常温搅拌3天。反应结束,在反应液中加甲基叔丁基醚,倾倒,固体不用10%甲醇/二氯甲烷溶解,加硅胶粉(5g),干法上样,柱层析。用5%-25%甲醇/二氯甲烷洗脱得产品0.3g,产率44%。MALDI-TOF MS测定的分子量范围为72500-74070。
56-89的合成:
45-114
称取Boc-L-Lys(Fmoc)-OH(20g,42.6857mmol)、Gly-OBn(14.4g,42.6857mmol)、HBTU(24g,64.0286mmol)、HOBT(8.65g,64.0286mmol)投入500mL反应瓶中,加入DMF(40mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(31.7mL,192.085mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,蒸干得产品26克。
45-115
称取化合物45-114(26g,42.6857mmol),加入二氯甲烷(20mL),再加入TFA(14mL,190.2855mmol),超声溶解,搅拌反应。反应结束,反应液浓缩,再用乙酸乙酯(100mL)溶解,加饱和氯化钠溶液,分离有机相,水相用乙酸乙酯萃取3次(50mL×3),直至水相无产品,合并有机相,再用饱和食盐水清洗一次(50mL),浓缩蒸干得产品22g。
45-124
称取Boc-L-Lys(Boc)-OH(7.3g,21.334mmol)、45-115(11g,21.334mmol)、HBTU(12.1363g,32.0016mmol)、HOBT(4.3241g,32.0016mmol)投入500mL反应瓶中,加入DMF(80mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(15mL,96.003mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,干法上样,柱层析,用50%-100%乙酸乙酯/石油醚梯度洗脱得产品15克,产率83%。
45-126
称取化合物45-124(15g,17.7725mmol),加入二氯甲烷(30mL),再加入TFA(39mL,533.1754mmol),超声溶解,搅拌反应。反应结束,反应液浓缩,再用乙酸乙酯(100mL)溶解,加饱和碳酸氢钠溶液至水相显碱性,分离有机相,水相用乙酸乙酯萃取3次(150mL×3),直至水相无产品,合并有机相,再用饱和食盐水清洗一次(150mL),浓缩蒸干得产品11.44g。
45-127
称取Boc-L-Lys(Boc)-OH(13.022g,37.5911mmol)、45-126(11.4g,17.0868mmol)、HBTU(19.5538g,51.5604mmol)、HOBT(6.9668g,51.5604mmol)投入500mL反应瓶中,加入DMF(80mL)溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(25.4mL,153.7812mmol),-5℃条件下反应过夜。反应结束,用纯水与乙酸乙酯萃取处理反应,饱和食盐水清洗,浓缩有机相,干法上样,柱层析,用1%-55甲醇/二氯甲烷梯度洗脱得产品18克,产率81%。
45-135
取反应物45-127(1.1g,0.8458mmol)置于250mL烧瓶中,加DMF溶液(50mL),加入吗啉(1.4745mL,16.9155mmoL),常温搅拌反应,3小时后,反应结束。饱和食盐水(150mL)和乙酸乙酯(200mL),分离有机相,水相用乙酸乙酯萃取3次(150mL×3),水相中无产品,合并有机相,用饱和食盐水清洗2次(150mL×2),有机相蒸干得产品0.912克。
21-221
称赤藓醇(4.5g,36.849mmol)投500mL两颈反应瓶中,加四氢呋喃(60mL)超声均匀,置于0℃条件下搅拌,通入氮气保护后,加叔丁醇钾(200mL,184.245mmol),0℃下搅拌2小时后,加入溴乙酸苄酯(29.187mL,184.245mmol),再搅拌3小时后移至常温下反应。反应结束,用纯水与乙酸乙酯萃取处理反应液,浓缩有机相,干法上样,柱层析。用1%-2%乙酸乙酯/石油醚梯度洗脱得产品5g,产率20%。
38-120
称21-221(0.64g,0.9793mmol)与10%Pd/C(100mg)投入氢化反应釜中,缓慢加入DMF(30mL)搅拌溶解,通入氢气(300psi),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得产品的DMF溶液,直接投下一步反应。
52-86
称取45-135(0.5g,0.46mmol)、HBTU(0.22g,0.576mmol)、HOBT(0.08g,0.576mmol)投入250mL反应瓶中,加入38-120(0.096mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.3mL,1.728mmol),-5℃条件下反应过夜。反应结束,在反应液中加纯水,抽滤,干法上样,柱层析。用2%甲醇/二氯甲烷洗脱得产品0.32g,产率50%。
52-88
称52-86(0.32g,0.0694mmol)与10%Pd/C(75mg)投入氢化反应釜中,缓慢加入DMF(50mL)搅拌溶解,通入氢气(2MPa),常温搅拌过夜。次日,用装有硅藻土的砂芯漏斗抽滤反应液,除去Pd/C,得产品的DMF溶液,直接投下一步反应。
52-90
称取M-NH2HCl-10K(3.065g,0.2914mmol)、HBTU(0.1579g,0.4164mmol)、HOBT(0.0562g,0..4164mmol)投入250mL反应瓶中,加入52-88(0.0667mmol)的DMF溶液溶解,-5℃条件下搅拌30分钟后。缓慢滴加DIEA(0.257mL,1.5545mmol),-5℃条件下反应1小时后移至常温下低速避光反应。反应结束,在反应液中加甲基叔丁基醚,抽滤,干法上样,柱层析。用5%-6%甲醇/二氯甲烷洗脱得产品1.2g。
1H-NMR(400MHz,DMSO-d6)δ7.98-7.88(m,14H),7.71-7.60(m,15H),7.58-7.47(m,16H),7.45-7.31(m,6H),5.76(s,28H),3.8-3.35(m,3810H),3.20-3.12(m,13H),2.91-2.80(m,10H),2.71-2.60(m,14H),2.33-2.30(m,13H),2.25-2.09(m,22H),1.36-1.28(m,51H),1.20-1.11(m,49H),1.05-1.00(m,96H),
52-92
称取化合物52-90(1.5g,0.0325mmol),加入二氯甲烷(10mL),再加入TFA(0.78mL,10.4mol),超声溶解,搅拌反应。反应结束,在反应液中加甲醇(30mL),加过量碳酸钾,搅拌30分钟,抽滤,烘干得产品2g。
1H-NMR(400MHz,DMSO-d6)δ8.25-8.02(m,12H),7.92-7.80(m,11H),7.71-7.65(m,2H),5.76-5.60(m,8H),5.58-5.50(m,23H),3.75-3.70(m,27H),3.60-3.56(m,35H),3.51-3.40(m,3810H),2.71-2.65(m,12H),2.60-2.55(m,16H),1.71-1.65(m,15H),1.60-1.55(m,28H),1.52-1.47(m,17H),1.16-1.00(m,18H)
56-86
称取52-92(0.0325mmol)、N-乙酰基-L-半胱氨酸(0.046g,0.286mmol,购于伊诺凯)、HBTU(0.147g,0.39mmol)、HOBT(0.052g,0.0.39mmol)投入250mL反应瓶中,DMF溶液溶解,-5℃条件下避光搅拌30分钟后。缓慢滴加DIEA(0.193mL,1.17mmol),-5℃条件下反应1小时后移至常温下避光反应。反应结束,在反应液中加甲基叔丁基醚倾倒多次得产品1.5g。
1H-NMR(400MHz,DMSO-d6)δ8.03-8.00(m,56H),5.75-5.68(m,5H),4.45-4.37(m,26H),3.55-5.45(m,3810H),1.81-1.75(m,80H),1.51-1.45(m,26H),1.40-1.33(m,133H),0.85-0.83(m,12H),
56-89
称取56-86(0.0325mmol)、MI-AH-PPT-iRGD(1.04g,0.65mmol,购于丹港生物)、投入250mL反应瓶中,加DMSO(50mL)溶液溶解,40℃条件下避光搅拌2天,常温搅拌3天。反应结束,在反应液中加甲基叔丁基醚,倾倒,固体不用10%甲醇/二氯甲烷溶解,加硅胶粉(5g),干法上样,柱层析。用5%-25%甲醇/二氯甲烷洗脱得产品0.3g,产率44%。
1H-NMR(400MHz,DMSO-d6)δ8.35-8.30(m,7H),8.24-8.20(m,14H),8.17-8.10(m,48H),8.07-8.01(m,32H),8.00-7.94(m,20H),7.86-7.80(m,24H),7.78-7.71(m,34H),7.69-7.51(m,31H),7.45-7.37(m,144H),7.31-7.22(m,28H),5.69-5.60(m,5H),5.07-4.95(m,14H),4.40-4.35(m,61H),4.23-4.06(m,78H),3.76-3.65(m,120H),3.55-3.40(m,3810H),2.82-2.76(m,35H),2.65-2.60(m,16H),2.11-2.05(m,25H),1.78-1.70(m,125H),1.31-1.28(m,57H),1.23-119(m,150H),1.17-1.14(m,146H),1.10-1.04(m,317H),0.93-0.84(m,41H),0.80-0.76(m,240H)
实施例2聚乙二醇偶联药物增效剂对于抗癌药物在人乳腺癌MDA-MB-231细胞BALB/c裸鼠皮下移植瘤模型的抗肿瘤作用的增效试验
1、配制方法
供试品:
1)量取适量的抗癌药物(例如49-166),加入适量的生理盐水,配制成合适浓度的溶液。
2)量取适量的待测聚乙二醇偶联药物增效剂(例如45-164)+抗癌药物(例如49-166),加入适量的生理盐水,配制成合适浓度的溶液。
阴性对照:直接使用生理盐水。
配制好的供试品和对照品给药前于2~8℃或冰盒保存,给药剩余的供试品和对照品按医疗垃圾处理。
2、细胞及实验动物
人乳腺癌细胞MDA-MB-231:来源于中国医学科学院基础所细胞资源中心,培养条件为RPMI1640+10%FBS,37℃、5%CO2培养。
动物种属&品系:BALB/C裸鼠
动物等级:SPF级
实验动物来源:北京维通利华实验动物技术有限公司
肿瘤接种时周龄:约4-5周。
肿瘤接种时体重:约15~18g。同性别动物的体重在平均体重的80%~120%之间。
性别与数量:雌性,订购96只小鼠,筛选成模动物48只用于最终实验,剩余动物转交兽医或安乐死。
动物饲养于独立通风系统(IVC)中,每笼最多饲养同组6只动物,SPF级动物房,环境条件控制在室温20~26℃,相对湿度40%~70%,光照12小时明暗交替。在检疫驯养期间和试验期间,每天提供合格的鼠料(生产单位:北京科澳协力饲料有限公司),动物均自由摄食并自由饮水。
3、模型的建立
复苏MDA-MB-231细胞,进行细胞传代扩增,待扩增至足量细胞数时,收集处于对数生长期的细胞,准备进行细胞接种。
根据实际细胞数,调整细胞浓度在1×108个/mL,与基质胶(Matrigel BasementMembrance Matrix,BD公司)按1:1体积混合,得到浓度为5×107个/mL的细胞悬液,以0.2mL/只接种于96只小鼠右侧腋窝皮下。在接种后观察肿瘤生长情况,最终筛选得到肿瘤体积为77.30~292.27mm3的48只成瘤动物用于试验。
4、动物分组和给药剂量
根据瘤体积和体重随机分为8组,其中,1组(阴性对照组,生理盐水)、6组(49-166,48mg/kg)、8组(49-166+45-164,48+176mg/kg),每组6只。静脉注射,各组在D1、D4、D7、D10、D13、D18、D21、D24给药,D27动物实施安乐死。
5、实验结果
5.1一般临床观察
观察频率及时间:实验期间,所有动物每天进行两次大体观察。
观察内容:包括动物精神状态、行为活动、摄食情况等。
5.2体重
检测动物:所有动物
检测时间:接收后、接种前、分组(即首次给药前)(D1)、以后每周2次、安乐死前称取动物体重。动物发生意外死亡或濒死安乐死时也称重。
5.3瘤径的测量
检测动物:所有动物
检测时间:分组(即首次给药当天为D1)、首次给药后每周2次、安乐死前,游标卡尺测量并记录肿瘤长、短径,计算肿瘤体积。
按照以下公式计算肿瘤体积:
V=1/2×长径×短径2
试验期间每天2次观察动物一般临床症状,共进行10次体重和瘤径测量,安乐死后剥取肿瘤,称量肿瘤重量。计算瘤体积、相对肿瘤体积RTV、相对肿瘤增殖率T/C%、瘤重抑制率IRTW%。
6、结果分析与评价
统计分析:本试验使用统计学软件SPSS13.0对数据进行处理,计量资料以平均值±标准误来表示。具体分析过程如下:
用单因素方差分析(ANOVA)进行统计分析,如果ANOVA有统计学意义(P≤0.05)且方差齐性,用Tukey test进行组间比较分析,若方差不齐性,则用Dunnett’s T3 test进行组间比较分析。
6.1根据肿瘤体积进行疗效评价
按照以下公式计算相对肿瘤体积(RTV)和相对肿瘤增殖率T/C%:
RTV=Vt/V0
Vt:每天测量肿瘤得到的瘤体积
V0:初始瘤体积(给药前)
T/C%=给药组的RTV平均值/对照组的RTV平均值×100%
以给药组相对肿瘤增殖率T/C%≤40%且该组RTV与阴性对照组RTV相比P≤0.05为有效,有肿瘤增长抑制作用;反之,如果T/C%>40%,则为对肿瘤增长无抑制作用。
6.2根据肿瘤重量进行疗效评价
实验结束后,剥离肿瘤结节并进行称重,比较各组间肿瘤重量的差异以进一步计算肿瘤抑制率IRTW,以IRTW≥60%为有效性辅助参考指标,计算公式如下:
IRTW(%)=(W模型组-W给药组)/W模型组×100%
6.3大体解剖观察
对实验期间死亡动物以及观察期结束后安乐死动物进行大体解剖,对主要脏器进行观察,看是否有肉眼可见明显异常。
6.4照片记录
对安乐死动物及肿瘤进行照相。
具体结果如下:
整个试验过程中,各组动物未见明显异常。各组动物体重试验期间缓慢增长,各供试品组与第1组间未见显著性差异(P>0.05)。
阴性对照组(1组)整个试验中,肿瘤逐渐增长,至试验结束时(D27),1组平均瘤体积为2962.92±2176.59mm3,平均RTV为19.14±12.01;6、8组的平均肿瘤体积分别为1690.27±785.04mm3、1273.37±358.45mm3,平均RTV分别为13.03±5.43、10.55±5.73。
各组肿瘤增长趋势见图1。
至实验结束时(D27),6、8组T/C%值分别为68.08%、55.10%,其IRTV%分别为31.92%、44.90%。
试验结束时,动物安乐死后称量瘤重,1、6、8组的平均瘤重分别为2.555±2.207g、0.990±0.399g、0.684±0.165g。6、8组的IRTW%分别为61.24%、73.21%。
各组肿瘤重量抑制率示意图见图2。
结论:在本实验条件下,供试品49-166在48mg/kg剂量下、49-166在48mg/kg剂量与45-164在176mg/kg剂量联合(49-166+45-164),尾静脉注射给药对人乳腺癌MDA-MB-231细胞BALB/c裸鼠皮下移植瘤的生长均有明显的抑制作用,49-166+45-164的抑瘤作用显著优于49-166。
发明人通过以上实验和结果发现,本发明的聚乙二醇偶联药物增效剂可以作为抗癌药物对皮下移植瘤(例如,人乳腺癌MDA-MB-231细胞BALB/c裸鼠皮下移植瘤)的抗肿瘤作用的增效剂,且增效明显。
Claims (10)
1.式(I)所示的聚乙二醇偶联药物增效剂或其药学上可接受的盐,
其中:
PEG1为单臂聚乙二醇链段,PEG1通过羰基与L1相连或者PEG1的末端带有氨基或活化的氨基,PEG1的数均分子量为5k-40k,优选为5k-10k或10k-40k,更优选为10k;
Y1、Y0各自独立地选自 r1为1、2、3、4、5或6,r1优选为1、2、3或4,r1更优选为3或4,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2;
P为-LV-T;
LV选自 各r0独立地为1、2、3、4、5或6,各r0独立地优选为3、4、5或6,各r0独立地更优选为5或6,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2;
3.制备权利要求1所述的聚乙二醇偶联药物增效剂或其药学上可接受的盐的方法,其包括:
M1、L1、Y1、Y0如权利要求1所限定,
Pro2为羧基的保护基,优选地,Pro2为苄氧基,
Pro1为氨基或羧基的保护基,优选地,Pro1为氨基的保护基时,Pro1为叔丁氧羰基,优选地,Pro1为羧基的保护基时,Pro1为叔丁氧基;
5.组合物,其包含权利要求1-2任一项所述的聚乙二醇偶联药物增效剂或其药学上可接受的盐;任选地,所述组合物还包含一种或多种药学上可接受的辅料。
6.权利要求5的组合物,其中,所述组合物还包含抗癌药物。
7.权利要求6的组合物,其中,所述抗癌药物为式(A)所示的聚乙二醇偶联药物或其药学上可接受的盐,
其中:
j为3或4;
PEG2为单臂聚乙二醇链段,PEG2通过羰基与L2相连或者PEG2的末端带有氨基或活化的氨基,PEG2的数均分子量为5k-40k,优选为5k-10k或10k-40k,更优选为5k;
Z2、Z1、Z0各自独立地为r1为1、2、3、4、5或6,r1优选为1、2、3或4,r1更优选为3或4,各r2独立地为1、2、3、4、5或6,各r2独立地优选为1、2、3或4,各r2独立地更优选为1或2,
Q为N-AC;
AC为SB7、NPB、SN38、LPT、PCB、DOX、PTX或AXT,优选为PTX或SN38。
9.权利要求1-2任一项所述的聚乙二醇偶联药物增效剂或其药学上可接受的盐或者权利要求5所述的组合物在制备药物中的用途,所述药物用于增强治疗和/或预防疾病的疗效;
优选地,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
10.权利要求6-8任一项所述的组合物在制备治疗和/或预防疾病的药物中的用途,所述疾病为权利要求6-8任一项所限定的抗癌药物所治疗的疾病;
优选地,所述疾病为癌症,所述癌症选自:结肠癌、白血病、淋巴瘤、膀胱癌、骨癌、脑瘤、髓母细胞瘤、胶质瘤、乳腺癌、腺瘤/类癌、肾上腺皮质癌、胰岛细胞癌、子宫颈癌、子宫内膜癌、卵巢癌、结肠直肠癌、皮肤癌、食管癌、眼癌、胆囊癌、胃癌、头颈癌、肝癌、黑色素瘤、卡波氏肉瘤、肾癌、口腔癌、肺癌、鼻咽癌、神经母细胞瘤、卵巢癌、胰腺癌、甲状腺癌、甲状旁腺阴茎癌、前列腺癌、尿道癌、阴道癌、外阴癌、肛门癌、肉瘤,以及所述癌症的转移。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020107374152 | 2020-07-28 | ||
CN202010737415 | 2020-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113995846A true CN113995846A (zh) | 2022-02-01 |
CN113995846B CN113995846B (zh) | 2024-03-22 |
Family
ID=79921268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110824029.1A Active CN113995846B (zh) | 2020-07-28 | 2021-07-21 | 聚乙二醇偶联药物增效剂、其制备方法及用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230348671A1 (zh) |
EP (1) | EP4190360A1 (zh) |
JP (1) | JP2023537248A (zh) |
CN (1) | CN113995846B (zh) |
WO (1) | WO2022022354A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022242488A1 (zh) * | 2021-05-18 | 2022-11-24 | 重庆阿普格雷生物科技有限公司 | 聚乙二醇偶联药物及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104987504A (zh) * | 2015-04-23 | 2015-10-21 | 南京明臻医药科技有限公司 | 聚乙二醇化拉帕替尼及其注射剂和制备方法 |
CN107670048A (zh) * | 2017-08-30 | 2018-02-09 | 重庆阿普格雷生物科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
CN108350022A (zh) * | 2015-11-12 | 2018-07-31 | 内布拉斯加大学董事会 | 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2009114154A (ru) * | 2006-09-15 | 2010-10-20 | Энзон Фармасьютикалз, Инк. (Us) | Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры |
CN107670050B (zh) * | 2017-08-30 | 2019-06-07 | 重庆阿普格雷生物科技有限公司 | 基于pki-587的抗癌中间体和聚乙二醇偶联抗癌药物、及其制备方法和应用 |
US20220047713A1 (en) * | 2018-04-02 | 2022-02-17 | Jenkem Technology Co., Ltd. (Beijing) | Cell-penetrating peptide-multiarm pol yethylene glycol-drug conjugate having targeting property and application thereof |
AU2020389657A1 (en) * | 2019-11-28 | 2022-06-23 | Chongqing Upgra Biotechnology Co., Ltd. | Polyethylene glycol conjugate medicament, preparation method therfor and use thereof |
-
2021
- 2021-07-21 JP JP2023504146A patent/JP2023537248A/ja active Pending
- 2021-07-21 CN CN202110824029.1A patent/CN113995846B/zh active Active
- 2021-07-21 WO PCT/CN2021/107555 patent/WO2022022354A1/zh active Application Filing
- 2021-07-21 US US18/016,897 patent/US20230348671A1/en active Pending
- 2021-07-21 EP EP21850002.3A patent/EP4190360A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104987504A (zh) * | 2015-04-23 | 2015-10-21 | 南京明臻医药科技有限公司 | 聚乙二醇化拉帕替尼及其注射剂和制备方法 |
CN108350022A (zh) * | 2015-11-12 | 2018-07-31 | 内布拉斯加大学董事会 | 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法 |
CN107670048A (zh) * | 2017-08-30 | 2018-02-09 | 重庆阿普格雷生物科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
CN109843333A (zh) * | 2017-08-30 | 2019-06-04 | 重庆阿普格雷生物科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
CHOI,SUNG WON等: "Multifunctional siRNA Delivery System: Polyelectrolyte Complex Micelles of Six-arm PEG Conjugate of siRNA and Cell Penetrating Peptide with Crosslinked Fusogenic Peptide", BIOTECHNOL. PROG., vol. 26, no. 1, pages 1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022242488A1 (zh) * | 2021-05-18 | 2022-11-24 | 重庆阿普格雷生物科技有限公司 | 聚乙二醇偶联药物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN113995846B (zh) | 2024-03-22 |
EP4190360A1 (en) | 2023-06-07 |
WO2022022354A1 (zh) | 2022-02-03 |
JP2023537248A (ja) | 2023-08-31 |
US20230348671A1 (en) | 2023-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110167598A (zh) | Tlr激动剂化合物的多臂聚合物缀合物以及相关的免疫治疗方法 | |
CN111514309B (zh) | 一种聚乙二醇偶联药物、其制备方法及用途 | |
JP6854759B2 (ja) | 腫瘍微環境によって特異的活性化する小分子標的結合体およびその使用 | |
WO2021104120A1 (zh) | 一种聚乙二醇偶联药物、其制备方法及用途 | |
JP2019519508A (ja) | マルチアーム重合標的抗がんコンジュゲート | |
CN111001012A (zh) | 一种亲水碳酸酯型抗体偶联药物 | |
WO2021103342A1 (zh) | 一种聚乙二醇偶联药物、其制备方法及应用 | |
WO2021109351A1 (zh) | 一种聚乙二醇偶联药物、其制备方法及应用 | |
WO2018192550A1 (zh) | 多臂靶向抗癌偶联物 | |
CN113995846A (zh) | 聚乙二醇偶联药物增效剂、其制备方法及用途 | |
CN108727583B (zh) | 多臂靶向抗癌偶联物 | |
CN107854693A (zh) | 整合素受体靶向的抗癌偶联物 | |
US20240115713A1 (en) | Polyethylene glycol conjugate drug, and preparation method therefor and use thereof | |
CN106631957A (zh) | 一种靶向FAP‑alpha酶的抗肿瘤化合物及其制备方法与应用 | |
CN110152013B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN110418653B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
WO2022242488A1 (zh) | 聚乙二醇偶联药物及其用途 | |
CN108727582A (zh) | 靶向抗癌偶联物 | |
CN108727584B (zh) | 抗癌偶联物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |